WCG Clinical

OCTOBER 9, 2023

The dermatology market is embarking on tremendous growth and sponsors need to be ready. Over the last 12 months, dermatology-focused studies have increased by roughly 20%, with top focus areas including psoriasis, atopic dermatitis, and alopecia. This rapid growth brings new challenges. Efficiency and speed are critical.

Dermatology 59

Dermatology Trials Marketing Clinical Trials 59

pharmaphorum

APRIL 29, 2022

The tool has been used to assess more than 23,000 patients and discover almost 1,500 cases of cancer, whilst reducing the number if dermatology appointments needed by more than 4,700, said the company.

Dermatology 145

Dermatology Containment Marketing Development 145

Pharmaceutical Technology

MAY 30, 2023

Lecanemab by Eisai Co Ltd, a monoclonal antibody therapy marketed for Alzheimer’s disease, is predicted to achieve the most significant commercial debut. Genmab AS’s epcoritamab presents as the top European drug launch and only oncological therapy. These drugs are set to make a combined $4.34bn in sales in 2028.

Drugs 264

Drugs Sales Antibody Dermatology 264

BioTech 365

MARCH 15, 2021

Dermatology Drugs Market Research Report 2020 – Global Industry Analysis and Growth Forecast to 2030 – ResearchAndMarkets.com Dermatology Drugs Market Research Report 2020 – Global Industry Analysis and Growth Forecast to 2030 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Dermatology Drugs Market Research (..)

Dermatology 40

Dermatology Marketing Research Drugs 40

Outsourcing Pharma

MAY 23, 2022

With Veeva Link for Key People, LEO Pharma is looking to deepen its efforts to engage with knowledgeable medical professionals in the dermatology community.

Dermatology 52

Dermatology Development Drugs Regulation 52

BioPharma Reporter

AUGUST 22, 2023

LEO Pharma has acquired Timber Pharmaceuticals, in a deal that will add an âattractiveâ late stage asset to its pipeline in medical dermatology, the company said.

Dermatology 52

Dermatology Regulation Marketing 52

BioTech 365

NOVEMBER 3, 2020

Global Dermatological Therapeutics Market Report 2020-2025: Atopic Dermatitis Segment is Expected to Register a Robust Growth – ResearchAndMarkets.com Global Dermatological Therapeutics Market Report 2020-2025: Atopic Dermatitis Segment is Expected to Register a Robust Growth – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The (..)

Dermatology 40

Dermatology Marketing 40

Fierce Pharma

OCTOBER 25, 2024

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets with new data readouts.

Dermatology 88

Dermatology Trials Marketing Drugs 88

BioTech 365

APRIL 26, 2021

United States Generic Drugs Market Report 2020-2026: Focus on CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti-infective & Oncology – ResearchAndMarkets.com United States Generic Drugs Market Report 2020-2026: Focus on CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti-infective & (..)

Generic Drugs 40

Generic Drugs Dermatology Hormones Marketing 40

BioPharma Reporter

FEBRUARY 13, 2024

Alys Pharmaceuticals, an immuno-dermatology focused company, has launched with $100 million financing by Medicxi and an R&D pipeline enabled by multiple platform technologies.

Dermatology 52

Dermatology Regulation Marketing 52

Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical 172

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 172

Pharmaceutical Technology

APRIL 19, 2023

Telehealth is on the rise , with its market expected to be worth $3.8bn by 2030, according to GlobalData. In Canada, access to dermatological care is extremely limited, with only 1.7 In Canada, access to dermatological care is extremely limited, with only 1.7

Dermatology 130

Dermatology Pharmacy Branding Marketing 130

Pharmaceutical Technology

APRIL 19, 2023

Arcutis Biotherapeutics president and CEO Frank Watanabe stated: “The acceptance of the NDA for roflumilast foam marks a major milestone toward our goal of bringing a steroid-free, topical foam treatment option to market, addressing a significant unmet need for individuals living with seborrheic dermatitis. “If

Dermatology 130

Dermatology Trials Drugs Regulation 130

BioPharma Reporter

NOVEMBER 21, 2023

A partnership combining an integrated drug creation platform with a company specializing in dermatological expertise will deliver life-changing medicines to patients.

Medicine 95

Medicine Dermatology Drugs Regulation 95

XTalks

APRIL 17, 2023

These results are very promising for patients with atopic dermatitis,” said Jonathan Silverberg, MD, professor of dermatology at George Washington University School of Medicine & Health Sciences and co-investigator of the studies, in the company’s press release. percent to be worth $26.5 billion by 2028.

Dermatology 97

Dermatology Antibody Clinical Trials Clinical Trials 97

pharmaphorum

SEPTEMBER 16, 2022

Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable stress in the daily lives of patients and often negatively affect their day-to-day and long-term well-being. About the interviewee. Dr. Thyssen, MD, Ph.D.

Dermatology 100

Dermatology Trials Drugs Development 100

pharmaphorum

SEPTEMBER 15, 2022

” The Swiss Competition Commission (COMCO) arrived unexpectedly at Novartis at dawn on Tuesday morning, to gather information on an unidentified dermatology drug, as part of a wider investigation into the drugmaker by the European Commission.

Dermatology 118

Dermatology Production Pharma Companies Marketing 118

Pharmaceutical Technology

DECEMBER 5, 2022

Incyte has signed a partnership and licence agreement with CMS subsidiary CMS Aesthetics to develop and market ruxolitinib cream to treat autoimmune and inflammatory dermatologic ailments in Greater China and some Southeast Asian countries.

Dermatology 130

Dermatology FDA Approval Production Sales 130

pharmaphorum

DECEMBER 29, 2021

The green light comes later than Leo hoped, as the FDA turned down the dermatology specialist’s first attempt last year, despite making it through regulatory reviews in the EU, UK, Canada and UAE where it is already launched as Adtralza. Leo now says it will start rolling the new product out in February. billion in the same year.

Sales 111

Sales Dermatology Marketing Allergies 111

The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. INDIANAPOLIS , Oct.

Dermatology 52

Dermatology Development Medicine Clinical Trials 52

STAT News

DECEMBER 2, 2022

And a fragmented clinical trials industry has made it a prime target for private equity, which often consolidates markets by merging companies.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Dermatology 98

Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Drug Channels

JULY 11, 2022

Director, Cell Therapy Operations and Patient Services, Gamida Cell Austin Fisher, Executive Director, CART Patient Support and Distribution, Autolus Chris Boneham, Vice President Market Access U.S., Drug Channels readers will save 10% off the current registration rate when they use code 22DC10 *.

Pharmacy 98

Pharmacy Dermatology Manufacturing Drugs 98

XTalks

MARCH 18, 2025

Incytes recent announcement on the topline results from two Phase III clinical trials of povorcitinib in patients with hidradenitis suppurativa has stirred both hope and caution in the market. Though as we anticipated, we believe it will likely be relegated to later-line, post-biologics setting given lesser efficacy and safety baggage.

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59

Delveinsight

SEPTEMBER 28, 2021

Innovent, UNION Therapeutics Set to Advance Dermatology Market in China. Innovent Biologics and UNION therapeutics have announced a strategic and licensing collaboration to develop and commercialize Orismilast , a next-generation PDE4 inhibitor for inflammatory dermatology conditions in China.

Clinical Trials 80

Clinical Trials Clinical Trials Trials Dermatology 80

Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Drugs Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Drugs Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 24, 2023

Douglas provides products in various therapeutic areas which include psoriasis, eczema, dermatitis, chicken pox, constipation, laxative, neonatal, hormone regulation, dermatology, cardiovascular and measles, among others. The company also offers contract manufacturing and laboratory services.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

FEBRUARY 24, 2023

Douglas provides products in various therapeutic areas which include psoriasis, eczema, dermatitis, chicken pox, constipation, laxative, neonatal, hormone regulation, dermatology, cardiovascular and measles, among others. The company also offers contract manufacturing and laboratory services.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

pharmaphorum

FEBRUARY 3, 2021

For the last three years he has served as executive vice president, growth markets commercial, at Israeli pharma Teva. Spanish drugmaker Almirall has lined up its new CEO following the departure of Peter Guenter, who left to lead Merck KGaA’s healthcare unit earlier this month. Gianfranco Nazzi.

Dermatology 52

Dermatology Marketing Branding Medicine 52

pharmaphorum

NOVEMBER 9, 2021

However, the rise in research and development has created a crowded market that healthcare professionals struggle to navigate. Market access advice for launching in crowded landscapes. Market access advice for launching in crowded landscapes. The landscape is booming with treatment innovations. DOWNLOAD THE FULL EBOOK HERE.

Life Science 52

Life Science Marketing Development Research 52

pharmaphorum

JULY 22, 2021

Happify Health has launched a prescription digital therapeutic (DTx) – called Ensemble – that can assist the treatment of people with both major depressive disorder and generalised anxiety disorder in the US market.

Dermatology 98

Dermatology Marketing Development Research 98

pharmaphorum

APRIL 28, 2021

Eli Lilly has walked away from a major indication for its blockbuster hopeful mirikizumab, shelving plans to file it for psoriasis as the market is getting much too congested. . The post Crowded psoriasis market cuts Lilly’s mirikizumab ambitions appeared first on. Johnson & Johnson’s $7.7

Marketing 52

Marketing Trials Drugs Antibody 52

XTalks

MARCH 6, 2023

The portfolio contains approximately forty-five commercial products, four products in the pipeline, and forty approved non-marketed products, many of which are generics focused on women’s health. The US has always been an important market for us,” said Chief Executive Officer of Dr. Reddy’s, Erez Israeli, in a statement.

Production 98

Production Branding Dermatology Hormones 98

XTalks

MARCH 24, 2023

The company recently presented a pooled analysis from clinical studies of their DermaSensor skin cancer detection device at the American Academy of Dermatology (AAD) 2023 Annual Meeting. The global skin cancer diagnostics market is anticipated to reach $5.48 billion by 2028 from $3.36 percent, according to The Insight Partners.

Dermatology 97

Dermatology Clinical Trials Clinical Trials Sales 97

The Pharma Data

NOVEMBER 8, 2020

Almirall strengthens its leadership in medical dermatology by reinforcing its management team in France and obtaining reimbursement in France of Ilumetri ® (tildrakizumab) for treating moderate to severe chronic plaque psoriasis in adults. Dermatology shows resilience in Europe and initial signs of recovery in the US.

Dermatology 52

Dermatology Sales Marketing Production 52

pharmaphorum

JULY 5, 2022

With more than 500 dermatology clinical trials currently underway, it is often heard that there is a ‘’competition for participants’’. Trial organisers face intense competition to find and recruit eligible patients for atopic dermatitis studies.

Trials 118

Trials Clinical Trials Clinical Trials Dermatology 118